These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 38070596

  • 1. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).
    Ou SI, Hagopian GG, Zhang SS, Nagasaka M.
    J Thorac Oncol; 2024 May; 19(5):706-718. PubMed ID: 38070596
    [Abstract] [Full Text] [Related]

  • 2. TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers.
    Thawani R, Repetto M, Keddy C, Nicholson K, Jones K, Nusser K, Beach CZ, Harada G, Drilon A, Davare MA.
    bioRxiv; 2024 Jan 19. PubMed ID: 38293020
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer.
    Desilets A, Repetto M, Drilon A.
    Clin Transl Med; 2024 Oct 19; 14(10):e70017. PubMed ID: 39402859
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
    Terrones M, Deben C, Rodrigues-Fortes F, Schepers A, de Beeck KO, Van Camp G, Vandeweyer G.
    J Transl Med; 2024 Mar 03; 22(1):234. PubMed ID: 38433235
    [Abstract] [Full Text] [Related]

  • 9. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
    Keddy C, Shinde P, Jones K, Kaech S, Somwar R, Shinde U, Davare MA.
    Mol Cancer Ther; 2022 Feb 03; 21(2):336-346. PubMed ID: 34907086
    [Abstract] [Full Text] [Related]

  • 10. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
    Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT.
    Cancer Discov; 2018 Oct 03; 8(10):1227-1236. PubMed ID: 30093503
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.
    Ou SI, Zhu VW.
    Lung Cancer; 2019 Apr 03; 130():201-207. PubMed ID: 30885345
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N.
    Clin Cancer Res; 2015 Jan 01; 21(1):166-74. PubMed ID: 25351743
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.